Azvudine - Wikipedia
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. [3] It was discovered for the treatment of hepatitis C [ 4 ] and has since been investigated for use against other viral …
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have …
Azvudine: Uses, Interactions, Mechanism of Action - DrugBank …
2020年12月23日 · Mechanism of action. Azvudine is a nucleoside reverse transcriptase inhibitor that acts against HIV, HBV, and HCV. Some studies also show that it is able to modulate the …
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have …
Real‐world effectiveness and safety of oral azvudine versus ...
6 天之前 · Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. ... the antitumor mechanism and expanded use …
使用国产新冠口服药「阿兹夫定」，这些要点需要了解！ - 丁香园
2023年1月4日 · 阿兹夫定（Azvudine） 是新型核苷类逆转录酶和辅助蛋白 Vif（Viral infectivity factor）双靶点抑制剂，是我国拥有完全自主知识产权并拥有全球专利的抗病毒 1.1 类创新药 …
Single-cell sequencing studies demonstrated that Azvudine promoted thymus function. These studies indicate that Azvudine may cure COVID-19 patients through the thymus-homing …
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 …
2023年9月5日 · Azvudine (FNC, RO-0622), a first-in-class nucleoside-based prodrug developed by Henan Sincere Biotech Co., Ltd., was granted conditional marketing authorization by the …
The first Chinese oral anti-COVID-19 drug Azvudine launched
2022年11月8日 · In a phase 3 multicenter, randomized, double-blind, placebo-controlled study (n = 280), Azvudine significantly shortened the symptom improvement time of patients with …
The first Chinese oral anti-COVID-19 drug Azvudine launched
2022年11月8日 · In a phase 3 multicenter, randomized, double-blind, placebo-controlled study (n = 280), Azvudine significantly shortened the symptom improvement time of patients with …